A detailed history of La Financiere De L'Echiquier transactions in Bio N Tech Se stock. As of the latest transaction made, La Financiere De L'Echiquier holds 234,539 shares of BNTX stock, worth $26.8 Million. This represents 0.85% of its overall portfolio holdings.

Number of Shares
234,539
Previous 214,112 9.54%
Holding current value
$26.8 Million
Previous $19.8 Million 4.58%
% of portfolio
0.85%
Previous 0.88%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Jul 18, 2024

BUY
$80.36 - $102.87 $1.64 Million - $2.1 Million
20,427 Added 9.54%
234,539 $18.8 Million
Q1 2024

Apr 29, 2024

BUY
$88.96 - $112.35 $3.78 Million - $4.78 Million
42,514 Added 24.78%
214,112 $19.8 Million
Q4 2023

Jan 25, 2024

BUY
$90.91 - $112.75 $2.46 Million - $3.05 Million
27,035 Added 18.7%
171,598 $18.1 Million
Q3 2023

Nov 09, 2023

BUY
$98.5 - $125.08 $553,865 - $703,324
5,623 Added 4.05%
144,563 $15.7 Million
Q2 2023

Aug 10, 2023

BUY
$102.58 - $129.66 $4.26 Million - $5.38 Million
41,482 Added 42.56%
138,940 $15 Million
Q1 2023

May 03, 2023

BUY
$122.57 - $153.67 $1.93 Million - $2.42 Million
15,719 Added 19.23%
97,458 $12.1 Million
Q4 2022

Feb 09, 2023

BUY
$118.43 - $186.05 $43,582 - $68,466
368 Added 0.45%
81,739 $12.3 Million
Q3 2022

Nov 02, 2022

BUY
$127.65 - $183.11 $15,062 - $21,606
118 Added 0.15%
81,371 $11 Million
Q2 2022

Aug 05, 2022

BUY
$123.25 - $186.24 $58,667 - $88,650
476 Added 0.59%
81,253 $12.1 Million
Q1 2022

May 05, 2022

BUY
$126.25 - $231.85 $1.97 Million - $3.61 Million
15,574 Added 23.89%
80,777 $13.8 Million
Q4 2021

Feb 08, 2022

BUY
$216.64 - $362.52 $14.1 Million - $23.6 Million
65,203 New
65,203 $16.8 Million

Others Institutions Holding BNTX

About BioNTech SE


  • Ticker BNTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 242,684,992
  • Market Cap $27.7B
  • Description
  • BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II...
More about BNTX
Track This Portfolio

Track La Financiere De L'Echiquier Portfolio

Follow La Financiere De L'Echiquier and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of La Financiere De L'Echiquier, based on Form 13F filings with the SEC.

News

Stay updated on La Financiere De L'Echiquier with notifications on news.